Premium
Topiramate reduces levodopa‐induced dyskinesia in the MPTP‐lesioned marmoset model of Parkinson's disease
Author(s) -
Silverdale Monty A.,
Nicholson S.L.,
Crossman A.R.,
Brotchie J.M.
Publication year - 2005
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.20345
Subject(s) - dyskinesia , levodopa , topiramate , parkinson's disease , medicine , psychology , marmoset , ampa receptor , neuroscience , pharmacology , epilepsy , disease , glutamate receptor , receptor , biology , paleontology
Overactive AMPA receptor‐mediated transmission may be involved in the pathogenesis of levodopa‐induced dyskinesia. The mechanism of action of the anticonvulsant drug topiramate involves attenuation of AMPA receptor‐mediated transmission. In this study, the potential antidyskinetic action of topiramate was examined in the MPTP‐lesioned marmoset model of Parkinson's disease and levodopa‐induced dyskinesia. Topiramate significantly reduced levodopa‐induced dyskinesia, without affecting the antiparkinsonian action of levodopa. Topiramate represents an exciting potential novel therapeutic approach to levodopa‐induced dyskinesia in patients with Parkinson's disease. © 2004 Movement Disorder Society